1 | younger | 7,051 |
2 | heavier | 456 |
3 | lighter | 262 |
4 | sicker | 76 |
5 | taller | 60 |
6 | leaner | 29 |
7 | fatter | 23 |
8 | non-symptomatic | 21 |
9 | ct-colonography | 17 |
10 | donor/recipient | 12 |
11 | bupropion-treated | 11 |
12 | autoantibody-negative | 10 |
13 | non-abused | 10 |
14 | non-enrolled | 10 |
15 | ivs4 | 9 |
16 | mosf | 9 |
17 | non-ambulant | 9 |
18 | 8cs | 8 |
19 | fitter | 8 |
20 | non-localized | 8 |
21 | non-ms | 8 |
22 | noncarrier | 8 |
23 | primetime | 8 |
24 | trial-ineligible | 8 |
25 | 3679 | 7 |
26 | itha | 7 |
27 | non-wt | 7 |
28 | ob/ow | 7 |
29 | 2,284 | 6 |
30 | ambidextrous | 6 |
31 | chm-diet | 6 |
32 | mi/hf- | 6 |
33 | moslem | 6 |
34 | non-pcg | 6 |
35 | nonhardened | 6 |
36 | oaa | 6 |
37 | ptca-treated | 6 |
38 | r53h | 6 |
39 | venogenic | 6 |
40 | yosemite | 6 |
41 | +ld | 5 |
42 | 4029 | 5 |
43 | 70-year | 5 |
44 | akinetic-rigid | 5 |
45 | aosg | 5 |
46 | bezafibrate-treated | 5 |
47 | co-managed | 5 |
48 | dc-5ari | 5 |
49 | hematometra | 5 |
50 | ifnγko-aldosterone | 5 |
51 | l-capd | 5 |
52 | lamca | 5 |
53 | language-inclusive | 5 |
54 | low-hdl-c | 5 |
55 | mi/hf+ | 5 |
56 | non-af | 5 |
57 | non-minority | 5 |
58 | noncolonized | 5 |
59 | nonhypoxemic | 5 |
60 | nonnarrative | 5 |
61 | nonsurviving | 5 |
62 | rfi+ | 5 |
63 | sicl | 5 |
64 | sirukumab-treated | 5 |
65 | theophylline-treated | 5 |
66 | 1,644 | 4 |
67 | 50-59-year-old | 4 |
68 | 65-year | 4 |
69 | 74-year | 4 |
70 | acamprosate-treated | 4 |
71 | adq-mel | 4 |
72 | atomoxetine-buspirone | 4 |
73 | average-weight | 4 |
74 | eig | 4 |
75 | hla-dq2/8-positive | 4 |
76 | k0fast | 4 |
77 | legendary | 4 |
78 | modified-sna | 4 |
79 | non-statins | 4 |
80 | older-onset | 4 |
81 | pc-pep | 4 |
82 | receptor-defective | 4 |
83 | white-british | 4 |
84 | 11,064 | 3 |
85 | 11,794 | 3 |
86 | 11/95 | 3 |
87 | 2,380 | 3 |
88 | 4039 | 3 |
89 | 5991 | 3 |
90 | 6019 | 3 |
91 | aai- | 3 |
92 | amoxicilin | 3 |
93 | audio-saq | 3 |
94 | autotriggering | 3 |
95 | azli-treated | 3 |
96 | black-african | 3 |
97 | ca-125+ | 3 |
98 | cream-treated | 3 |
99 | deflates | 3 |
100 | fdmc | 3 |
101 | fluid-overloaded | 3 |
102 | group-nr | 3 |
103 | he-allergic | 3 |
104 | hfhs-hf | 3 |
105 | kushen-gancao | 3 |
106 | linezolid- | 3 |
107 | low-fitness | 3 |
108 | non-bls | 3 |
109 | non-hispanic-whites | 3 |
110 | pib-positive | 3 |
111 | statin-switch | 3 |
112 | tid28w | 3 |
113 | vaccine-treated | 3 |
114 | 10,873 | 2 |
115 | 11,928 | 2 |
116 | 13-years | 2 |
117 | 140/less | 2 |
118 | 15-24-year | 2 |
119 | 160/less | 2 |
120 | 19/103 | 2 |
121 | 2,575 | 2 |
122 | 2,719 | 2 |
123 | 2002/2004 | 2 |
124 | 2080-2099 | 2 |
125 | 210-ma | 2 |
126 | 31/51 | 2 |
127 | 4,632 | 2 |
128 | 4,679 | 2 |
129 | 4,810 | 2 |
130 | 4/114 | 2 |
131 | 42/100 | 2 |
132 | 45,528 | 2 |
133 | 4952 | 2 |
134 | 5,994 | 2 |
135 | 54,624 | 2 |
136 | 7,592 | 2 |
137 | 8,354 | 2 |
138 | aai-monitored | 2 |
139 | bakuo | 2 |
140 | biopsy-positive | 2 |
141 | caries-susceptible | 2 |
142 | chfw | 2 |
143 | ci-p | 2 |
144 | developer- | 2 |
145 | endometroid | 2 |
146 | first-calving | 2 |
147 | fpmsc | 2 |
148 | gestrinone-treated | 2 |
149 | gonococcus-infected | 2 |
150 | hi-ha | 2 |
151 | hi-pu | 2 |
152 | hsem | 2 |
153 | hypokalemics | 2 |
154 | isoflurane-derived | 2 |
155 | left-wing | 2 |
156 | light-coloured | 2 |
157 | mericitabine- | 2 |
158 | methionine/methionine | 2 |
159 | methoxybutropate | 2 |
160 | non-addicted | 2 |
161 | non-lyophilized | 2 |
162 | non-sleepy | 2 |
163 | non-switch | 2 |
164 | nonhydrochlorothiazide | 2 |
165 | ns-a | 2 |
166 | oprm_ga | 2 |
167 | over-70 | 2 |
168 | p1p1 | 2 |
169 | p4-primed | 2 |
170 | post-tam | 2 |
171 | pre-stented | 2 |
172 | rh/k34 | 2 |
173 | rhesus-negative | 2 |
174 | shr-controls | 2 |
175 | steady-minded | 2 |
176 | syntocinon-ergometrine | 2 |
177 | tachygastria | 2 |
178 | touristic | 2 |
179 | under-weight | 2 |
180 | vaqta | 2 |
181 | yzh- | 2 |
182 | 13,720 | 1 |
183 | 16-29-year | 1 |
184 | 19,747 | 1 |
185 | 3,354 | 1 |
186 | 5-mg-risedronate | 1 |
187 | 60+/mean | 1 |
188 | 60-69-year | 1 |
189 | aged/mean | 1 |
190 | anti-hbs-negative | 1 |
191 | children.higher | 1 |
192 | cinnamon-treated | 1 |
193 | comt_gg | 1 |
194 | courted | 1 |
195 | crystal-ta2o5 | 1 |
196 | females-to-males | 1 |
197 | fifty-year | 1 |
198 | flibanserin- | 1 |
199 | g1-tt4 | 1 |
200 | g1b-infected | 1 |
201 | hp-0c-np-g | 1 |
202 | int/hot | 1 |
203 | ketoconazole- | 1 |
204 | knee-oa | 1 |
205 | lagb-treated | 1 |
206 | leptin- | 1 |
207 | long-ranging | 1 |
208 | low-risks | 1 |
209 | median-anxious | 1 |
210 | mmf+everolimus | 1 |
211 | nectin-4 | 1 |
212 | non-child-welfare-involved | 1 |
213 | non-dysphonic | 1 |
214 | non-emitters | 1 |
215 | nonshedders | 1 |
216 | outscore | 1 |
217 | outsold | 1 |
218 | over-hydrated | 1 |
219 | pcv7-primed | 1 |
220 | peri-ovarian | 1 |
221 | pmr-treated | 1 |
222 | post-gnrha | 1 |
223 | rilpivirine-treated | 1 |
224 | rsb2 | 1 |
225 | seventy-year | 1 |
226 | surgical-risk | 1 |
227 | tptd- | 1 |
228 | were109 | 1 |
229 | wmft-time | 1 |
230 | ɛ3ɛ3 | 1 |
231 | γ=0.33 | 1 |
1 | +ld | 5 |
2 | 1,644 | 4 |
3 | 10,873 | 2 |
4 | 11,064 | 3 |
5 | 11,794 | 3 |
6 | 11,928 | 2 |
7 | 11/95 | 3 |
8 | 13,720 | 1 |
9 | 13-years | 2 |
10 | 140/less | 2 |
11 | 15-24-year | 2 |
12 | 16-29-year | 1 |
13 | 160/less | 2 |
14 | 19,747 | 1 |
15 | 19/103 | 2 |
16 | 2,284 | 6 |
17 | 2,380 | 3 |
18 | 2,575 | 2 |
19 | 2,719 | 2 |
20 | 2002/2004 | 2 |
21 | 2080-2099 | 2 |
22 | 210-ma | 2 |
23 | 3,354 | 1 |
24 | 31/51 | 2 |
25 | 3679 | 7 |
26 | 4,632 | 2 |
27 | 4,679 | 2 |
28 | 4,810 | 2 |
29 | 4/114 | 2 |
30 | 4029 | 5 |
31 | 4039 | 3 |
32 | 42/100 | 2 |
33 | 45,528 | 2 |
34 | 4952 | 2 |
35 | 5,994 | 2 |
36 | 5-mg-risedronate | 1 |
37 | 50-59-year-old | 4 |
38 | 54,624 | 2 |
39 | 5991 | 3 |
40 | 60+/mean | 1 |
41 | 60-69-year | 1 |
42 | 6019 | 3 |
43 | 65-year | 4 |
44 | 7,592 | 2 |
45 | 70-year | 5 |
46 | 74-year | 4 |
47 | 8,354 | 2 |
48 | 8cs | 8 |
49 | aai- | 3 |
50 | aai-monitored | 2 |
51 | acamprosate-treated | 4 |
52 | adq-mel | 4 |
53 | aged/mean | 1 |
54 | akinetic-rigid | 5 |
55 | ambidextrous | 6 |
56 | amoxicilin | 3 |
57 | anti-hbs-negative | 1 |
58 | aosg | 5 |
59 | atomoxetine-buspirone | 4 |
60 | audio-saq | 3 |
61 | autoantibody-negative | 10 |
62 | autotriggering | 3 |
63 | average-weight | 4 |
64 | azli-treated | 3 |
65 | bakuo | 2 |
66 | bezafibrate-treated | 5 |
67 | biopsy-positive | 2 |
68 | black-african | 3 |
69 | bupropion-treated | 11 |
70 | ca-125+ | 3 |
71 | caries-susceptible | 2 |
72 | chfw | 2 |
73 | children.higher | 1 |
74 | chm-diet | 6 |
75 | ci-p | 2 |
76 | cinnamon-treated | 1 |
77 | co-managed | 5 |
78 | comt_gg | 1 |
79 | courted | 1 |
80 | cream-treated | 3 |
81 | crystal-ta2o5 | 1 |
82 | ct-colonography | 17 |
83 | dc-5ari | 5 |
84 | deflates | 3 |
85 | developer- | 2 |
86 | donor/recipient | 12 |
87 | eig | 4 |
88 | endometroid | 2 |
89 | fatter | 23 |
90 | fdmc | 3 |
91 | females-to-males | 1 |
92 | fifty-year | 1 |
93 | first-calving | 2 |
94 | fitter | 8 |
95 | flibanserin- | 1 |
96 | fluid-overloaded | 3 |
97 | fpmsc | 2 |
98 | g1-tt4 | 1 |
99 | g1b-infected | 1 |
100 | gestrinone-treated | 2 |
101 | gonococcus-infected | 2 |
102 | group-nr | 3 |
103 | he-allergic | 3 |
104 | heavier | 456 |
105 | hematometra | 5 |
106 | hfhs-hf | 3 |
107 | hi-ha | 2 |
108 | hi-pu | 2 |
109 | hla-dq2/8-positive | 4 |
110 | hp-0c-np-g | 1 |
111 | hsem | 2 |
112 | hypokalemics | 2 |
113 | ifnγko-aldosterone | 5 |
114 | int/hot | 1 |
115 | isoflurane-derived | 2 |
116 | itha | 7 |
117 | ivs4 | 9 |
118 | k0fast | 4 |
119 | ketoconazole- | 1 |
120 | knee-oa | 1 |
121 | kushen-gancao | 3 |
122 | l-capd | 5 |
123 | lagb-treated | 1 |
124 | lamca | 5 |
125 | language-inclusive | 5 |
126 | leaner | 29 |
127 | left-wing | 2 |
128 | legendary | 4 |
129 | leptin- | 1 |
130 | light-coloured | 2 |
131 | lighter | 262 |
132 | linezolid- | 3 |
133 | long-ranging | 1 |
134 | low-fitness | 3 |
135 | low-hdl-c | 5 |
136 | low-risks | 1 |
137 | median-anxious | 1 |
138 | mericitabine- | 2 |
139 | methionine/methionine | 2 |
140 | methoxybutropate | 2 |
141 | mi/hf+ | 5 |
142 | mi/hf- | 6 |
143 | mmf+everolimus | 1 |
144 | modified-sna | 4 |
145 | mosf | 9 |
146 | moslem | 6 |
147 | nectin-4 | 1 |
148 | non-abused | 10 |
149 | non-addicted | 2 |
150 | non-af | 5 |
151 | non-ambulant | 9 |
152 | non-bls | 3 |
153 | non-child-welfare-involved | 1 |
154 | non-dysphonic | 1 |
155 | non-emitters | 1 |
156 | non-enrolled | 10 |
157 | non-hispanic-whites | 3 |
158 | non-localized | 8 |
159 | non-lyophilized | 2 |
160 | non-minority | 5 |
161 | non-ms | 8 |
162 | non-pcg | 6 |
163 | non-sleepy | 2 |
164 | non-statins | 4 |
165 | non-switch | 2 |
166 | non-symptomatic | 21 |
167 | non-wt | 7 |
168 | noncarrier | 8 |
169 | noncolonized | 5 |
170 | nonhardened | 6 |
171 | nonhydrochlorothiazide | 2 |
172 | nonhypoxemic | 5 |
173 | nonnarrative | 5 |
174 | nonshedders | 1 |
175 | nonsurviving | 5 |
176 | ns-a | 2 |
177 | oaa | 6 |
178 | ob/ow | 7 |
179 | older-onset | 4 |
180 | oprm_ga | 2 |
181 | outscore | 1 |
182 | outsold | 1 |
183 | over-70 | 2 |
184 | over-hydrated | 1 |
185 | p1p1 | 2 |
186 | p4-primed | 2 |
187 | pc-pep | 4 |
188 | pcv7-primed | 1 |
189 | peri-ovarian | 1 |
190 | pib-positive | 3 |
191 | pmr-treated | 1 |
192 | post-gnrha | 1 |
193 | post-tam | 2 |
194 | pre-stented | 2 |
195 | primetime | 8 |
196 | ptca-treated | 6 |
197 | r53h | 6 |
198 | receptor-defective | 4 |
199 | rfi+ | 5 |
200 | rh/k34 | 2 |
201 | rhesus-negative | 2 |
202 | rilpivirine-treated | 1 |
203 | rsb2 | 1 |
204 | seventy-year | 1 |
205 | shr-controls | 2 |
206 | sicker | 76 |
207 | sicl | 5 |
208 | sirukumab-treated | 5 |
209 | statin-switch | 3 |
210 | steady-minded | 2 |
211 | surgical-risk | 1 |
212 | syntocinon-ergometrine | 2 |
213 | tachygastria | 2 |
214 | taller | 60 |
215 | theophylline-treated | 5 |
216 | tid28w | 3 |
217 | touristic | 2 |
218 | tptd- | 1 |
219 | trial-ineligible | 8 |
220 | under-weight | 2 |
221 | vaccine-treated | 3 |
222 | vaqta | 2 |
223 | venogenic | 6 |
224 | were109 | 1 |
225 | white-british | 4 |
226 | wmft-time | 1 |
227 | yosemite | 6 |
228 | younger | 7,051 |
229 | yzh- | 2 |
230 | ɛ3ɛ3 | 1 |
231 | γ=0.33 | 1 |
1 | ca-125+ | 3 |
2 | mi/hf+ | 5 |
3 | rfi+ | 5 |
4 | linezolid- | 3 |
5 | tptd- | 1 |
6 | ketoconazole- | 1 |
7 | mericitabine- | 2 |
8 | mi/hf- | 6 |
9 | yzh- | 2 |
10 | aai- | 3 |
11 | flibanserin- | 1 |
12 | leptin- | 1 |
13 | developer- | 2 |
14 | 42/100 | 2 |
15 | 4,810 | 2 |
16 | 13,720 | 1 |
17 | over-70 | 2 |
18 | 2,380 | 3 |
19 | 31/51 | 2 |
20 | 5991 | 3 |
21 | p1p1 | 2 |
22 | 4,632 | 2 |
23 | 4952 | 2 |
24 | 7,592 | 2 |
25 | rsb2 | 1 |
26 | 19/103 | 2 |
27 | γ=0.33 | 1 |
28 | 10,873 | 2 |
29 | ɛ3ɛ3 | 1 |
30 | nectin-4 | 1 |
31 | 2002/2004 | 2 |
32 | 4/114 | 2 |
33 | 54,624 | 2 |
34 | rh/k34 | 2 |
35 | 1,644 | 4 |
36 | 3,354 | 1 |
37 | 8,354 | 2 |
38 | 11,064 | 3 |
39 | 2,284 | 6 |
40 | 11,794 | 3 |
41 | 5,994 | 2 |
42 | ivs4 | 9 |
43 | g1-tt4 | 1 |
44 | 2,575 | 2 |
45 | 11/95 | 3 |
46 | crystal-ta2o5 | 1 |
47 | 19,747 | 1 |
48 | 45,528 | 2 |
49 | 11,928 | 2 |
50 | were109 | 1 |
51 | 6019 | 3 |
52 | 2,719 | 2 |
53 | 4029 | 5 |
54 | 4039 | 3 |
55 | 4,679 | 2 |
56 | 3679 | 7 |
57 | 2080-2099 | 2 |
58 | ns-a | 2 |
59 | oaa | 6 |
60 | lamca | 5 |
61 | oprm_ga | 2 |
62 | hi-ha | 2 |
63 | post-gnrha | 1 |
64 | itha | 7 |
65 | tachygastria | 2 |
66 | 210-ma | 2 |
67 | modified-sna | 4 |
68 | knee-oa | 1 |
69 | hematometra | 5 |
70 | vaqta | 2 |
71 | low-hdl-c | 5 |
72 | he-allergic | 3 |
73 | nonhypoxemic | 5 |
74 | venogenic | 6 |
75 | non-dysphonic | 1 |
76 | non-symptomatic | 21 |
77 | touristic | 2 |
78 | fdmc | 3 |
79 | fpmsc | 2 |
80 | fluid-overloaded | 3 |
81 | steady-minded | 2 |
82 | co-managed | 5 |
83 | non-enrolled | 10 |
84 | p4-primed | 2 |
85 | pcv7-primed | 1 |
86 | nonhardened | 6 |
87 | aai-monitored | 2 |
88 | light-coloured | 2 |
89 | non-abused | 10 |
90 | ptca-treated | 6 |
91 | sirukumab-treated | 5 |
92 | lagb-treated | 1 |
93 | vaccine-treated | 3 |
94 | theophylline-treated | 5 |
95 | rilpivirine-treated | 1 |
96 | gestrinone-treated | 2 |
97 | bezafibrate-treated | 5 |
98 | acamprosate-treated | 4 |
99 | azli-treated | 3 |
100 | cream-treated | 3 |
101 | bupropion-treated | 11 |
102 | cinnamon-treated | 1 |
103 | pmr-treated | 1 |
104 | over-hydrated | 1 |
105 | g1b-infected | 1 |
106 | gonococcus-infected | 2 |
107 | non-addicted | 2 |
108 | pre-stented | 2 |
109 | courted | 1 |
110 | isoflurane-derived | 2 |
111 | non-child-welfare-involved | 1 |
112 | non-localized | 8 |
113 | non-lyophilized | 2 |
114 | noncolonized | 5 |
115 | akinetic-rigid | 5 |
116 | endometroid | 2 |
117 | +ld | 5 |
118 | 50-59-year-old | 4 |
119 | outsold | 1 |
120 | l-capd | 5 |
121 | nonhydrochlorothiazide | 2 |
122 | trial-ineligible | 8 |
123 | caries-susceptible | 2 |
124 | wmft-time | 1 |
125 | primetime | 8 |
126 | methionine/methionine | 2 |
127 | syntocinon-ergometrine | 2 |
128 | ifnγko-aldosterone | 5 |
129 | atomoxetine-buspirone | 4 |
130 | outscore | 1 |
131 | 5-mg-risedronate | 1 |
132 | methoxybutropate | 2 |
133 | yosemite | 6 |
134 | language-inclusive | 5 |
135 | anti-hbs-negative | 1 |
136 | rhesus-negative | 2 |
137 | autoantibody-negative | 10 |
138 | nonnarrative | 5 |
139 | receptor-defective | 4 |
140 | hla-dq2/8-positive | 4 |
141 | pib-positive | 3 |
142 | biopsy-positive | 2 |
143 | non-af | 5 |
144 | hfhs-hf | 3 |
145 | mosf | 9 |
146 | hp-0c-np-g | 1 |
147 | non-pcg | 6 |
148 | comt_gg | 1 |
149 | eig | 4 |
150 | long-ranging | 1 |
151 | autotriggering | 3 |
152 | nonsurviving | 5 |
153 | first-calving | 2 |
154 | left-wing | 2 |
155 | aosg | 5 |
156 | r53h | 6 |
157 | statin-switch | 3 |
158 | non-switch | 2 |
159 | white-british | 4 |
160 | dc-5ari | 5 |
161 | surgical-risk | 1 |
162 | sicl | 5 |
163 | adq-mel | 4 |
164 | post-tam | 2 |
165 | moslem | 6 |
166 | hsem | 2 |
167 | black-african | 3 |
168 | 60+/mean | 1 |
169 | aged/mean | 1 |
170 | peri-ovarian | 1 |
171 | amoxicilin | 3 |
172 | kushen-gancao | 3 |
173 | bakuo | 2 |
174 | ci-p | 2 |
175 | pc-pep | 4 |
176 | audio-saq | 3 |
177 | 70-year | 5 |
178 | 15-24-year | 2 |
179 | 74-year | 4 |
180 | 65-year | 4 |
181 | 16-29-year | 1 |
182 | 60-69-year | 1 |
183 | fifty-year | 1 |
184 | seventy-year | 1 |
185 | younger | 7,051 |
186 | children.higher | 1 |
187 | noncarrier | 8 |
188 | heavier | 456 |
189 | sicker | 76 |
190 | taller | 60 |
191 | leaner | 29 |
192 | lighter | 262 |
193 | fatter | 23 |
194 | fitter | 8 |
195 | group-nr | 3 |
196 | 8cs | 8 |
197 | hypokalemics | 2 |
198 | females-to-males | 1 |
199 | deflates | 3 |
200 | non-hispanic-whites | 3 |
201 | low-risks | 1 |
202 | non-bls | 3 |
203 | shr-controls | 2 |
204 | non-ms | 8 |
205 | non-statins | 4 |
206 | 13-years | 2 |
207 | nonshedders | 1 |
208 | non-emitters | 1 |
209 | 140/less | 2 |
210 | 160/less | 2 |
211 | low-fitness | 3 |
212 | mmf+everolimus | 1 |
213 | median-anxious | 1 |
214 | ambidextrous | 6 |
215 | chm-diet | 6 |
216 | older-onset | 4 |
217 | average-weight | 4 |
218 | under-weight | 2 |
219 | non-ambulant | 9 |
220 | donor/recipient | 12 |
221 | int/hot | 1 |
222 | k0fast | 4 |
223 | non-wt | 7 |
224 | hi-pu | 2 |
225 | tid28w | 3 |
226 | chfw | 2 |
227 | ob/ow | 7 |
228 | ct-colonography | 17 |
229 | non-sleepy | 2 |
230 | legendary | 4 |
231 | non-minority | 5 |